NRXPW — NRX Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1719406 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,068,000 | 437,000 | -4,748,000 | -1,430,000 | 11,903,000 | 6,713,000 | 25,719,000 |
| Dec 2025 | 983,000 | 575,000 | -4,624,000 | 360,000 | 12,956,000 | 7,797,000 | 28,893,000 |
| Sep 2025 | 242,000 | 145,000 | -4,024,000 | -5,890,000 | 14,996,000 | 7,184,000 | 40,751,000 |
| Jun 2025 | 0 | — | -3,730,000 | -17,581,000 | 4,838,000 | 2,910,000 | 40,453,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,112,000
Investing CF
$-249,000
Financing CF
$23,276,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-306,895,000
Inventory
—
Receivables
$161,000
ST Investments
—
EBIT TTM
$-27,952,000
Pretax Income TTM
$-28,623,000
Interest Exp TTM
$671,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,293,000
EBITDA
$-17,057,000
Free Cash Flow
$-8,542,125
Enterprise Value
—
Total Cash
$6,713,000
Total Debt
$934,000
Shares Out
—
Trailing EPS
$-6.25
Book Value
$-0.41
ROE
—
ROA
-110.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,225,000 | -16,224,000 | -28,622,000 | 12,956,000 | 28,893,000 | — | -14,112,000 |
| Dec 2024 | 0 | -18,502,000 | -25,126,000 | 3,651,000 | 26,874,000 | — | -10,637,000 |
| Dec 2023 | 0 | -27,587,000 | -30,150,000 | 7,315,000 | 19,048,000 | — | -21,657,000 |
| Dec 2022 | 0 | -44,335,000 | -39,754,000 | 25,816,000 | 18,407,000 | — | -39,755,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $949.47B | $1064.74 | — |
| JNJ | JOHNSON & JOHNSON | $554.09B | $230.18 | — |
| ABBV | AbbVie Inc. | $376.54B | $213.12 | — |
| MRK | Merck & Co., Inc. | $295.69B | $119.72 | — |
| AZN | ASTRAZENECA PLC | $290.30B | $187.19 | — |
News headlines (Yahoo Finance, 1h cache)
Here is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street Analysts
2026-05-24 11:49 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-18 11:00 · Yahoo
NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates
2026-05-15 21:55 · Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update
2026-05-14 11:00 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression an
2026-05-07 12:00 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine
2026-05-05 11:00 · Yahoo
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
2026-04-25 16:55 · Yahoo
NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program
2026-04-22 11:00 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality
2026-04-20 11:00 · Yahoo
NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications
2026-04-15 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.